Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -366.29% | -109.14% | 14.40% | 111.98% | 70.87% |
| Total Depreciation and Amortization | -24.80% | -24.29% | -22.13% | -24.47% | -28.02% |
| Total Amortization of Deferred Charges | -68.29% | -76.89% | -81.91% | -78.86% | -59.35% |
| Total Other Non-Cash Items | 925.20% | 441.62% | -11.43% | -122.07% | -118.63% |
| Change in Net Operating Assets | -263.73% | -3.57% | 10.85% | -222.63% | 1,133.46% |
| Cash from Operations | -188.41% | 42.33% | -39.55% | -163.07% | -88.99% |
| Capital Expenditure | 78.13% | 80.22% | 30.70% | -- | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -70.79% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,300.00% | -4,047.37% | -- | 165.56% | 161.12% |
| Cash from Investing | -794.18% | -2,397.66% | -678.12% | 194.00% | 210.64% |
| Total Debt Issued | -55.21% | -20.67% | -38.37% | 426.34% | 527.24% |
| Total Debt Repaid | 88.44% | 88.26% | 88.19% | -627.49% | -448.80% |
| Issuance of Common Stock | 338.92% | 328.04% | 328.04% | 27.63% | -17.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -118.39% | -783.59% | -113.63% | -190.53% | 6.60% |
| Cash from Financing | 5,408.76% | 606.17% | 1,323.69% | 145.49% | 95.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,007.83% | 8,595.83% | 467.44% | -373.15% | 3,003.57% |